Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Chronic Evaluation of Novel Pacemaker System

NCT06056817 · tracked via the Priya Life Science USA tracker
Sponsor
Calyan Technologies
Phase
Not applicable
Started
2026-07-01
Last updated
2026-09-01

Condition(s) studied

Ventricular Pacing With Rate ResponseBradycardia

Investigational drug(s) / intervention(s)

Calyan Pacemaker

Calyan Pacemaker: The Calyan pacemaker is a device designed for implantation in the chest below the xiphoid process, and includes a FlexArm containing stimulation and sensing electrodes. The Calyan pacemaker is implanted using a set of delivery tools and clipped onto the xiphoid process; the FlexArm electrodes are oriented to make contact with the pericardial surface of the heart. Pacing parameters are adjusted wirelessly with a tablet-based programmer that communicates with the Calyan pacemaker via secure Bluetooth.

Study summary

The primary study objective is to evaluate the feasibility, initial clinical safety and potential effectiveness of the Calyan Pacemaker system.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 or above 2. Willing and capable of providing informed consent 3. Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC/AHA/HRS guidelines 4. A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being Exclusion Criteria: 1. Patients with complete AV block or other pacemaker-dependent conditions 2. Patients in whom a substernal device implant should be avoided: 1. Any prior sternotomy; 2. Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space; 3. Any marked sternal abnormality, such as pectus excavatum or pectus carinatum 4. Prior abdominal surgery in the epigastric region 5. Planned sternotomy 6. Prior or planned chest radiotherapy 7. Hiatal hernia that distorts mediastinal anatomy 8. Adhesions in the anterior mediastinal space 9. Severe obesity so that subxiphoid/substernal tunneling cannot be safely performed 3. Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal/substernal tunneling cannot be safely performed 4. Patients with a class III indication for a permanent pacemaker 5. Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing 6. Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device 7. Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device 8. Patients who have previously undergone an open-heart surgical procedure. 9. Patients with an active infection 10. Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery 11. Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis 12. Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19 13. Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding 14. Subjects with a life expectancy of less than 12 months 15. Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy 16. Patients with decompensated heart failure expected to worsen with chronic RV pacing 17. Patients with COPD with oxygen dependence

Primary outcome measure(s)

  • Incidence of procedure and device related serious adverse events (SAEs) — 3 months
    Rate of procedure and device related serious adverse events (SAEs) at 3 months post-implant.
  • Number of patients with successful chronic ventricular pacing — 3 months
    Proportion of patients with successful chronic ventricular pacing, including successful pacemaker implantation and chronic capture of the ventricle, during the 3-month primary follow-up period.

Trial sites (1)

FacilityCityRegionStatus
University of Minnesota Minneapolis Minnesota Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06056817 on ClinicalTrials.gov ↗ ← All trials in the USA